moxifloxacin has been researched along with Disease, Pulmonary in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Boorgula, GD; Gumbo, T; Heysell, SK; McShane, PJ; Pasipanodya, JG; Philley, JV; Srivastava, S | 1 |
| Chong, YP; Jo, KW; Lee, HJ; Park, YE; Shim, TS | 1 |
| Chang, CL; Chen, LC; Chien, JY; Hsueh, PR; Yu, CJ | 1 |
| Deshpande, D; Gumbo, T; Lee, PS; Pasipanodya, JG; Srivastava, S | 1 |
| Jo, KW; Kim, DS; Kim, S; Kim, WS; Lee, JY; Lee, SD; Shim, TS | 1 |
| Gumbo, T; Leff, R; Meek, C; Pasipanodya, J; Sherman, CM; Srivastava, S | 1 |
| Fujita, T; Kitamura, A; Miki, Y; Nakamura, H; Nakamura, T; Sakurai, T; Tomita, K; Toyoda, F | 1 |
| Jeon, K; Koh, WJ; Shin, SJ | 1 |
8 other study(ies) available for moxifloxacin and Disease, Pulmonary
| Article | Year |
|---|---|
An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease.
Topics: Anti-Bacterial Agents; Humans; Lung Diseases; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium kansasii | 2022 |
Clinical Outcome with Standard Regimen plus Clofazimine or Moxifloxacin in Cavitary Mycobacterium avium Complex Pulmonary Disease.
Topics: Anti-Bacterial Agents; Clofazimine; Humans; Lung Diseases; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Retrospective Studies | 2022 |
Different clinical features of patients with pulmonary disease caused by various Mycobacterium avium-intracellulare complex subspecies and antimicrobial susceptibility.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Female; Humans; Lung Diseases; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium avium; Mycobacterium avium-intracellulare Infection; Taiwan; Young Adult | 2020 |
A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Fluoroquinolones; Humans; Lung Diseases; Macrophages; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Organophosphates; Oxazoles; Rifabutin; THP-1 Cells | 2017 |
Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy.
Topics: Aged; Anti-Bacterial Agents; Clofazimine; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Linezolid; Lung Diseases; Male; Middle Aged; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Retreatment; Retrospective Studies; Rifabutin; Treatment Failure | 2014 |
Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease.
Topics: Anti-Bacterial Agents; Area Under Curve; Colony Count, Microbial; Dose-Response Relationship, Drug; Fluoroquinolones; Lung Diseases; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium kansasii; Reserpine; Sterilization | 2015 |
[A case of primary pulmonary nocardiosis with multiple pulmonary nodules successfully treated with moxifloxacin].
Topics: Adolescent; Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Humans; Lung Diseases; Male; Moxifloxacin; Nocardia Infections; Quinolines | 2009 |
Successful treatment of Mycobacterium massiliense lung disease with oral antibiotics only.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Aza Compounds; Bronchiectasis; Clarithromycin; Female; Fluoroquinolones; Humans; Lung Diseases; Moxifloxacin; Mycobacterium; Quinolines | 2013 |